# References — Legal KLOW

> Full citation list for every claim on legalklow.com. Sources include PubMed, PMC, ClinicalTrials.gov, peer-reviewed journals, and FDA regulatory publications.

Every claim on this site links to a primary source. Sort by year or filter by component.

## How to read this list

Eighteen primary sources anchor the claims on this site. The numbering used here matches the inline citation chips ([01] through [18]) throughout /index, /research, /dosage, and /faq. The table is sortable by year and filterable by component (GHK-Cu, BPC-157, TB-500, KPV, or multi-component) and by evidence type (preclinical, clinical, review, regulatory). Each entry links to its DOI or to PubMed/PMC, ClinicalTrials.gov, or the relevant journal page where available. Regulatory references (FDA Category 2 list, WADA Prohibited List, USADA advisory, OPSS bulletin) are cited inline by descriptive label rather than by numbered entry, since the underlying publications are updated periodically and the canonical version is the current official publication.

## Primary research literature

The table below is rendered by DataTables. The full reference data is duplicated in plain HTML beneath the table for screen-reader and crawler accessibility. Outbound links go to PubMed, PMC, peer-reviewed journals, and ClinicalTrials.gov — the only outbound links this site uses.

## Notes on the regulatory sources

The FDA Category 2 designation for BPC-157, KPV, injectable GHK-Cu, and the Thymosin Beta-4 fragment LKKTETQ was published as part of the Interim Policy on Compounding Using Bulk Drug Substances; the September 2023 update is the load-bearing publication. The WADA Prohibited List is updated annually; BPC-157's S0 listing has been continuous since the listing first appeared. The USADA athlete advisory on BPC-157 is published on the USADA Spirit of Sport blog. The DoD Operation Supplement Safety (OPSS) advisory is published at opss.org. The Tailor Made Compounding plea and related Department of Justice filings are matters of public record. The Evexias Medical Group and Farmakeio litigation challenging the procedural basis of the Category 2 placement was filed in late 2023; status updates are available through the Holt Law trade-press coverage and through the federal court docket. Where any regulatory source has been superseded by a more recent publication, the current official version is the canonical reference; readers should not rely on this site's snapshot when the underlying record has moved on.

## What is not cited on this site

Two categories of source are deliberately absent. First, commercial vendor pages — vendor product copy, vendor 'research summary' PDFs, and vendor-published 'stability data' do not appear in the citation list. Second, social-media posts, forum threads, and influencer commentary on any of the four KLOW components do not appear. The 2025 HSS Journal systematic review identified 36 indexed studies on BPC-157 musculoskeletal healing in over thirty years of literature [08]; the volume of online commentary on the same compound is orders of magnitude larger and is not a substitute for the indexed record.

## References

[1] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[2] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[3] Jiang YQ, et al. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. Journal of Cosmetic Dermatology. 2023. https://onlinelibrary.wiley.com/doi/10.1111/jocd.15763
[4] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/12919876/
[5] Cerovecki T, Bojanic I, Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Orthopaedic Research. 2010;28(8):1155-1161. https://pubmed.ncbi.nlm.nih.gov/20162718/
[6] Hsieh MJ, Liu HT, Wang CN, et al. BPC157, a peptide of body protective compounds, promotes vascular tube formation through VEGFR2-Akt-eNOS pathway. Journal of Molecular Histology. 2017;48(6):395-405. https://pubmed.ncbi.nlm.nih.gov/29143229/
[7] Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38330529/
[8] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
[9] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[10] Manna SK, Aggarwal BB. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. 2006;27(2):432-441. https://www.sciencedirect.com/science/article/abs/pii/S0196978105004560
[11] Wu Y, Sun M, Wang D, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioactive Materials. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10582360/
[12] Yang C, Merlin D, et al. Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology. 2024. https://www.cmghjournal.org/article/S2352-345X(24)00057-2/fulltext
[13] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[14] RegeneRx Biopharmaceuticals. A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds (NCT00598871). ClinicalTrials.gov. 2008. https://clinicaltrials.gov/study/NCT00598871
[15] Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. 2007;1(3):201-207. https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/
[16] Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL 14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. Journal of Pharmacological Sciences. 2008;108(1):7-17. https://www.sciencedirect.com/science/article/pii/S1347861319313696
[17] Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167. https://pubmed.ncbi.nlm.nih.gov/31158953/
[18] Multiple authors. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Cureus. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
[19] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[20] Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[21] Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[22] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/
[23] Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-637. https://pubmed.ncbi.nlm.nih.gov/12750433/

---

A source-linked reading room for the public regulatory record on KLOW — not a clinic, not a law firm, not a vendor.